Lipidomic Signatures Informs Intravenous Racemic Ketamine Associated Remission in Treatment-Resistant Depression: A Pilot Study

被引：0
|
作者：
Singh, Balwinder [1 ]
MahmoudianDehkordi, Siamak [1 ]
Voort, Jennifer Vande [1 ]
Han, Xianlin [1 ]
Port, John [1 ]
Frye, Mark [1 ]
Daouk, Rima Kaddurah [1 ]
机构：
[1] Mayo Clin, Coll Med, Rochester, MN USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2022年 / 47卷
关键词：
IV; Ketamine; Metabolomics Signature; Treatment; Resistant Depression; Open Label Trials;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
P227
引用
收藏
页码：192 / 192
页数：1
相关论文
共 50 条
  • [41] The Impact of Childhood Maltreatment on Intravenous Ketamine Outcomes for Adult Patients with Treatment-Resistant Depression
    O'Brien, Brittany
    Lijffijt, Marijn
    Wells, Allison
    Swann, Alan C.
    Mathew, Sanjay J.
    PHARMACEUTICALS, 2019, 12 (03)
  • [42] Intravenous Ketamine for Treatment-Resistant Major Depressive Disorder
    Covvey, Jordan R.
    Crawford, Alexis Noble
    Lowe, Denise K.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (01) : 117 - 123
  • [43] Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression
    Liu Weijian
    Zhou Yanling
    Zheng Wei
    Wang Chengyu
    Zhan Yanni
    Lan Xiaofeng
    Zhang Bin
    Li Hanqiu
    Chen Lijian
    Ning Yuping
    JOURNAL OF AFFECTIVE DISORDERS, 2019, 259 : 1 - 6
  • [44] Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression
    Joshua S. Siegel
    Ben J. A. Palanca
    Beau M. Ances
    Evan D. Kharasch
    Julie A. Schweiger
    Michael D. Yingling
    Abraham Z. Snyder
    Ginger E. Nicol
    Eric J. Lenze
    Nuri B. Farber
    Psychopharmacology, 2021, 238 : 1157 - 1169
  • [45] Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression
    Siegel, Joshua S.
    Palanca, Ben J. A.
    Ances, Beau M.
    Kharasch, Evan D.
    Schweiger, Julie A.
    Yingling, Michael D.
    Snyder, Abraham Z.
    Nicol, Ginger E.
    Lenze, Eric J.
    Farber, Nuri B.
    PSYCHOPHARMACOLOGY, 2021, 238 (04) : 1157 - 1169
  • [46] Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial
    Mathew, Sanjay J.
    Murrough, James W.
    aan het Rot, Marije
    Collins, Katherine A.
    Reich, David L.
    Charney, Dennis S.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 (01) : 71 - 82
  • [47] The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review
    Serafini, Gianluca
    Howland, Robert H.
    Rovedi, Fabiana
    Girardi, Paolo
    Amore, Mario
    CURRENT NEUROPHARMACOLOGY, 2014, 12 (05) : 444 - 461
  • [48] Copper Concentrations in Ketamine Therapy for Treatment-Resistant Depression
    Slupski, Jakub
    Cubala, Wieslaw Jerzy
    Gorska, Natalia
    Slupska, Anita
    Galuszko-Wegielnik, Maria
    BRAIN SCIENCES, 2020, 10 (12) : 1 - 9
  • [49] Use of Ketamine in Elderly Patients with Treatment-Resistant Depression
    Ribeiro, Carolina Medeiros da Frota
    Riva-Posse, Patricio
    CURRENT PSYCHIATRY REPORTS, 2017, 19 (12)
  • [50] Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?
    McIntyre, Roger S.
    Lipsitz, Orly
    Lui, Leanna M. W.
    Rodrigues, Nelson B.
    Lee, Yena
    Ho, Roger C.
    Subramaniapillai, Mehala
    Gill, Hartej
    Cha, Danielle S.
    Lin, Kangguang
    Teopiz, Kayla M.
    Nasri, Flora
    Mansur, Rodrigo B.
    Kratiuk, Kevin
    Rosenblat, Joshua D.
    JOURNAL OF AFFECTIVE DISORDERS, 2021, 292 : 714 - 719
12345